GS-441524 is an antiviral nucleoside analogue used to treat feline infectious peritonitis (FIP) in cats. It interferes with coronavirus RNA replication and has been evaluated in multiple clinical studies involving cats with FIP.

GS-441524 is currently not an FDA-approved veterinary drug specifically for FIP. FDA approval requires a sponsor to formally develop and submit a veterinary drug application with evidence on safety, effectiveness, manufacturing and labeling. In May 2024, the U.S. FDA acknowledged that no FDA-approved drug was available for FIP and stated that it does not intend to enforce certain new-animal-drug approval requirements for patient-specific compounded GS-441524 when prescribed by a veterinarian and applicable conditions are met. Gilead Sciences has also publicly explained its position on veterinary development. At Gilead's 2021 annual shareholder meeting, CEO Daniel O'Day referred a question about veterinary approval of remdesivir/GS-441524 to Chief Medical Officer Merdad Parsey, who said Gilead was not an animal-health company and did not plan to develop or commercialize products in animal care, while noting that the company had engaged with animal-health companies and enabled out-licensing of GS-441524 for veterinary development. Patent protection is another part of the commercial landscape, but there is no single verified rule that GS-441524 cannot receive veterinary approval until 2038. A published review of Gilead's remdesivir-related U.S. patent portfolio listed several patents expiring between 2029 and 2038, including patents with anticipated expiry dates in April and July 2038. Therefore, the absence of FDA approval should not be described simply as 'waiting for the patent to expire.' It reflects the need for a sponsor, regulatory submission, development strategy and applicable intellectual-property rights.

Yes. GS-441524 has been studied in cats with wet, dry, ocular and neurological presentations of FIP, and published clinical studies have reported successful treatment outcomes. Treatment should still be tailored and monitored for the individual cat.

No. Compounded GS-441524 products are not FDA-approved finished veterinary drugs. In the United States, the FDA currently allows certain patient-specific compounded GS-441524 products to be supplied for cats with FIP under veterinary prescription through enforcement discretion, but this is not the same as FDA approval. FDA approval normally requires formal review of the finished product's safety, effectiveness, manufacturing controls, labeling and quality standards. For cat owners, 'compounded by a pharmacy' should not automatically be interpreted as 'FDA approved' or 'FDA tested as a finished product.' When comparing GS-441524 products, useful quality considerations include product concentration and consistency, API identity and purity, finished-product potency, sterility for injectable formulations, batch traceability, storage conditions and the cat's clinical response during treatment.

Not necessarily. Price, pharmacy status or brand name alone does not prove superior clinical effectiveness. Published evidence supports GS-441524 as an antiviral for FIP, but those results do not automatically prove that every commercial or compounded formulation performs equally, or that one supplier is clinically superior to another. Treatment outcome can also depend on correct FIP diagnosis, appropriate mg/kg dosage, product quality and concentration accuracy, consistent daily dosing, weight-based dose adjustment, treatment adherence and monitoring of clinical and laboratory response. The most meaningful question is whether the cat is receiving the intended amount of GS-441524 consistently and responding appropriately to treatment.